TXMD

• Total net revenue for Q2 2022 was $28.6 million, up 24% from Q2 2021. Operating expenses declined by $11.4 million or 21%, and gross profit rose by 26%. • Completed divestiture of vitaCare business unit, used proceeds to repay $120 million of debt. • FDA approved supplemental new drug application for ANNOVERA, expecting reduced manufacturing batch rejections and increased product supply. • Entered into definitive agreement to sell company to EW Healthcare Partners, but it didn't gain sufficient shareholder support; recent financing and maturity extension provide additional runway for evaluating options. • Refocused resources towards commercialization of pharmaceutical products, leading to decline in R&D expenditures.

• Recent financing with Rubric Capital Management and maturity extension provide additional runway. • Board of Directors and management team are evaluating options, including seeking partners to refinance debt or pursuing other strategic alternatives.

Total net revenue for the quarter was $28.6 million. Sales of ANNOVERA were $18.3 million, an increase of $8.7 million or 91.2% compared to Q2 2021. Sales of IMVEXXY were $6.7 million, a decrease of $3.2 million or 32.2% compared to Q2 2021. Sales of BIJUVA were $2.7 million, an increase of $0.5 million or 23.1% compared to Q2 2021. Prescription vitamin sales were $0.9 million, a decrease of $0.5 million or 35.5% compared to Q2 2021.

• Potential issues with ANNOVERA manufacturing batch rejections were a concern, but steps taken to address root causes. • Inventory and supply chain challenges previously impacted product availability.

Q: Can you talk about employee retention rates given ambiguity?

A: Turnover is in a reasonable rate, working on communication and incentive schemes to keep field force engaged.

Q: How much is ANNOVERA revenue performance reflective of end demand?

A: Revenue was based on demand, with restocking of channels due to prior demand running ahead of inventory, and plan to continue moving forward.

Q: Concerns about ANNOVERA rejection rates and impact on long-term opportunity?

A: Root cause of rejections found and addressed, not expected to be an issue moving forward.

Q: Thoughts on shareholder vision and company's options post-tender process?

A: Recent financing and maturity extension enable maintaining operations and evaluating options like refinancing debt or strategic alternatives, with ample discussion in SEC filings.